Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Host APOBEC3G protein inhibits HCV replication through direct binding at NS3.

Zhu YP, Peng ZG, Wu ZY, Li JR, Huang MH, Si SY, Jiang JD.

PLoS One. 2015 Mar 26;10(3):e0121608. doi: 10.1371/journal.pone.0121608. eCollection 2015.

2.

Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus.

Peng ZG, Zhao ZY, Li YP, Wang YP, Hao LH, Fan B, Li YH, Wang YM, Shan YQ, Han YX, Zhu YP, Li JR, You XF, Li ZR, Jiang JD.

Hepatology. 2011 Apr;53(4):1080-9. doi: 10.1002/hep.24160.

PMID:
21480314
3.

Human-APOBEC3G-dependent restriction of porcine endogenous retrovirus replication is mediated by cytidine deamination and inhibition of DNA strand transfer during reverse transcription.

Jin SY, Choi HY, Kim HS, Jung YT.

Arch Virol. 2018 Jul;163(7):1907-1914. doi: 10.1007/s00705-018-3822-x. Epub 2018 Apr 2.

PMID:
29610985
4.

Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Chandra PK, Hazari S, Poat B, Gunduz F, Prabhu R, Liu G, Burioni R, Clementi M, Garry RF, Dash S.

Virol J. 2010 Jun 7;7:118. doi: 10.1186/1743-422X-7-118.

5.

The intracellular inhibition of HCV replication represents a novel mechanism of action by the innate immune Lactoferrin protein.

Picard-Jean F, Bouchard S, Larivée G, Bisaillon M.

Antiviral Res. 2014 Nov;111:13-22. doi: 10.1016/j.antiviral.2014.08.012. Epub 2014 Sep 1.

PMID:
25193851
6.

Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R.

Microbiol Mol Biol Rev. 2009 Jun;73(2):211-32. doi: 10.1128/MMBR.00040-08. Review.

7.

Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.

Mukherjee S, Weiner WS, Schroeder CE, Simpson DS, Hanson AM, Sweeney NL, Marvin RK, Ndjomou J, Kolli R, Isailovic D, Schoenen FJ, Frick DN.

ACS Chem Biol. 2014 Oct 17;9(10):2393-403. doi: 10.1021/cb500512z. Epub 2014 Aug 15.

8.

Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.

Provazzi PJ, Mukherjee S, Hanson AM, Nogueira ML, Carneiro BM, Frick DN, Rahal P.

PLoS One. 2015 Dec 10;10(12):e0144638. doi: 10.1371/journal.pone.0144638. eCollection 2015.

9.

Functional analysis of the two cytidine deaminase domains in APOBEC3G.

Li X, Ma J, Zhang Q, Zhou J, Yin X, Zhai C, You X, Yu L, Guo F, Zhao L, Li Z, Zeng Y, Cen S.

Virology. 2011 Jun 5;414(2):130-6. doi: 10.1016/j.virol.2011.03.014. Epub 2011 Apr 13.

10.

Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-33.

Wang S, Wu X, Pan T, Song W, Wang Y, Zhang F, Yuan Z.

J Gen Virol. 2012 Jan;93(Pt 1):83-92. doi: 10.1099/vir.0.033860-0. Epub 2011 Sep 28.

PMID:
21957124
11.

Inhibition of HCV replication by oxysterol-binding protein-related protein 4 (ORP4) through interaction with HCV NS5B and alteration of lipid droplet formation.

Park IW, Ndjomou J, Wen Y, Liu Z, Ridgway ND, Kao CC, He JJ.

PLoS One. 2013 Sep 17;8(9):e75648. doi: 10.1371/journal.pone.0075648. eCollection 2013.

12.

Nonstructural protein 5A (NS5A) and human replication protein A increase the processivity of hepatitis C virus NS5B polymerase activity in vitro.

Mani N, Yuzhakov A, Yuzhakov O, Coll JT, Black J, Saxena K, Fulghum JR, Lippke JA, Rao BG, Rijnbrand R, Kwong AD.

J Virol. 2015 Jan;89(1):165-80. doi: 10.1128/JVI.01677-14. Epub 2014 Oct 15.

13.

APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.

Li XY, Guo F, Zhang L, Kleiman L, Cen S.

J Biol Chem. 2007 Nov 2;282(44):32065-74. Epub 2007 Sep 12.

14.

A host YB-1 ribonucleoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle production.

Chatel-Chaix L, Germain MA, Motorina A, Bonneil É, Thibault P, Baril M, Lamarre D.

J Virol. 2013 Nov;87(21):11704-20. doi: 10.1128/JVI.01474-13. Epub 2013 Aug 28.

15.

Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G.

Cen S, Peng ZG, Li XY, Li ZR, Ma J, Wang YM, Fan B, You XF, Wang YP, Liu F, Shao RG, Zhao LX, Yu L, Jiang JD.

J Biol Chem. 2010 May 28;285(22):16546-52. doi: 10.1074/jbc.M109.085308. Epub 2010 Apr 2.

16.

Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.

McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B.

J Virol. 2015 May;89(10):5362-70. doi: 10.1128/JVI.03188-14. Epub 2015 Mar 4.

17.
18.

Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.

Derse D, Hill SA, Princler G, Lloyd P, Heidecker G.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2915-20. Epub 2007 Feb 13.

19.

DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication.

Kang X, Chen X, He Y, Guo D, Guo L, Zhong J, Shu HB.

Virology. 2013 Jan 20;435(2):385-94. doi: 10.1016/j.virol.2012.10.025. Epub 2012 Nov 5.

20.

Supplemental Content

Support Center